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ORIGINAL ARTICLES
From the American Venous Forum
One of the primary goals of the American
Venous Forum is education. The forum should
bring the latest information in the field to the med-
ical community interested in acute and chronic
venous disease. The success of this effort is best mea-
sured by the scientific content of the annual meet-
ings and the dissemination of information that fol-
lows. Is this effort successful? Does the educational
effort achieve its goal of improving the care of
patients and health care delivery? Does the informa-
tion reach the right audience? These are important
questions. Although no one argues about the mis-
sion, I am, at times, uncertain about the forum’s
effectiveness in changing the way we think and how
we carry out our business. Those of us in academic
life are fortunate to be challenged every day of our
lives by students, residents, and fellows. However,
even here one senses considerable resistance to
change. Habits are very difficult to break, and new
concepts are often difficult to accept. 
EDUCATIONAL FAILURE
Where have we failed? I mean this in a collective
sense, because it is not just the members of this
organization or other organizations who are fully
responsible for our lack of progress in key areas.
There is little doubt that a failure to detect a prob-
lem that costs a life represents the worst possible
outcome. One only need look at our society to
determine how such failures are handled at the pre-
sent time. The death of even one patient from
something that could have been prevented is taken
very seriously. In the case of acute deep vein throm-
bosis (DVT), we have collectively failed to correct a
concept that has cost untold lives. This relates to
the use of Homans’ sign as a screening test in
patients suspected of having DVT. Since the publi-
cation by Haeger, it has been well accepted that the
bedside diagnosis of acute DVT is very imprecise.1
It is well known that Homans’ sign is worthless, and
indeed dangerous, yet, for reasons that are mysteri-
ous to me, every medical student, resident, fellow,
and physician in the entire world appears to know
about this sign and roughly how to use it at the
bedside. It continues to be used even today. Can it
be stamped out?
What did Homans have to do with this physical
finding? In 1944, in a medical progress review in
the New England Journal of Medicine, he reviewed
the diagnostic aspect of DVT in some depth.2 It is
a bit ironic that he was aware of the seminal work
on venography by Gunnar Bauer, but dismissed the
method as being “rather untrustworthy.”3 Homans
notes in his review that the dorsiflexion sign (as he
described it) was positive in 42% of patients with
acute DVT. However, because he did not use
venography, the diagnoses had to be made on clin-
ical grounds alone. He noted that the use of his
name to identify this sign was not popularized by
him, but by Allen and his associates, who in 1943
wrote, “Homans’ sign is a term used in our clinic.”4
Dr. John Homans himself preferred to refer to it as
the “dorsiflexion sign.”2 It is interesting to specu-
late what might have happened if the test had not
had his name attached. Why his name remains so
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much a part of a physician’s vocabulary will remain
a mystery, but we all must continue to decry the
test’s application.
When I was asked to contribute the chapter on
peripheral vascular disease in Harrison’s Principles of
Internal Medicine, I left the term “Homans’ sign”
out. I refused to perpetuate its use or even its men-
tion. It is a pity that Homans’ name was attached to
such a worthless finding, because he made so many
contributions to our knowledge in this field.
EDUCATIONAL SUCCESS
Although Homans’ sign continues to be used
widely, the recognition that something else is needed
is appreciated by all who work in acute venous disease.
It is clear that a major success story in my lifetime is
the insistence on using objective testing to make the
diagnosis of acute DVT. Credit has to be given to
Gunnar Bauer, who in 1940 really defined the role of
venography and how it should be used.3 Yet, as noted
above, American surgeons were slow to accept this
test as being definitive. It is ironic that in 1957 Bauer
himself stated that it was no longer necessary to use
venography if one would simply pay attention to the
physical findings. He said, “I may seem to have dwelt
unduly long on a description of these symptoms, but
I am firmly convinced that if a combination of several
or many of the general and local signs are recorded,
one can be reasonably certain that early thrombosis is
present; it is no longer necessary to rely on phlebog-
raphy to establish the diagnosis. This method was of
great value as long as the whole problem was still in
the course of investigation, but it is quite superfluous
nowadays. The diagnosis can be made by means of
routine clinical methods.”5 This is, of course, not
true, and none of us would now use clinical symptoms
and signs as the gold standard.
Although Bauer no longer thought that the test
he popularized was needed, venography did become
the gold standard here and abroad. However, it was
beset by problems, not the least of which was the dis-
comfort it produced. With injections into veins on
the dorsum of the foot, the iliac veins were not seen
well in 20% of cases, and the deep femoral vein was
seen only 50% of the time. In addition, the myriad of
veins in the calf presented problems, even for the
experienced. It was common to use a stereo viewer in
an attempt to unravel what was and wasn’t there. In
addition, this examination was one that many radiol-
ogists were not comfortable doing. However, the
method was used extensively as the final arbiter in the
diagnosis and localization of venous thrombi from
the level of the calf to the iliac veins.
My own interest in diagnostic methods goes back
to 1968, when we first started applying continuous
wave Doppler to the study of the venous system and
comparing it with venography.6 In experienced
hands, this worked well for the major deep veins, but
it was indirect and subjective, with the diagnosis
depending on a single observer. Plethysmography
came along at about the same time and quickly
proved to be useful for screening purposes.7-10 It—
particularly the impedance method—became widely
used throughout the world, until ultrasonic duplex
scanning began to be applied to this area.11,12 Very
quickly, both venography and the indirect methods
largely disappeared from the scene. The indirect tests
established the diagnosis based on physiologic
changes, not anatomic findings. This is in contrast to
venography, which demonstrated the exact sites of
occlusion. Interestingly, the method most widely
tested against venography was the impedance testing
method. In fact, it was clear that a positive/negative
test could reliably determine for the physician which
form of therapy should be carried out. The test was
insensitive to calf vein thrombosis, but this did not
appear to be relevant in the subsequent development
of pulmonary embolism if the test was negative. It is
safe to say that the calf veins were totally ignored in
this phase of study of the venous system. It was con-
cluded, perhaps inconclusively so, that the calf veins
are not important as contributors to the overall spec-
trum of pulmonary embolism. However, this remains
an open question, and it is likely that more informa-
tion will become available in the next few years to set-
tle this issue.
The availability and application of ultrasonic
duplex scanning changed the entire landscape,
because we now had a noninvasive imaging and
Doppler method that could be used from the level
of the calf to the iliac veins and inferior vena cava.
Duplex scanning was initially applied only to the
carotid artery, but, with improvements in the tech-
nology, all the major veins of the upper and lower
extremities became available for study. The earliest
systems were “black and white,” which somewhat
limited their application, particularly to the veins of
the calf. However, with the availability of color, this
has changed. The use of color not only speeds up the
examination, but also makes vessel identification
quicker and more certain. Very quickly, venography
disappeared from the scene, with its use becoming
almost of historical interest only. Scanning has had
an enormous impact on clinical practice, but it has
created another set of problems. For example,
because the method is simple, noninvasive, and
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quick to perform, it is overused. At our institution,
the positive yield is in the range of 10% only. Is this
too low? Given the vagaries of the history and phys-
ical examination and the consequences of making
the wrong diagnosis, I would have to say no. I see
no readily available alternatives at the moment.
There is ongoing interest in the use of a screening
blood test, such as D-dimer, but this has not proven
to be a suitable screening test in limiting the need
for imaging. However, with time and more experi-
ence, one can predict that this is likely to occur.
Even given the low positive rate, I doubt seriously
that anyone would want us to return to the bedside
diagnosis or venography as the alternative. I have
no answer to this dilemma, but I am pleased that
physicians are, for the first time, taking full advan-
tage of a new technology to make a correct diagno-
sis and institute proper therapy. Our patients have
benefitted immensely from this practice. Perhaps
the availability of a very sensitive and specific blood
test that can be done and reported within a few
hours may limit the number of negative scans that
are reported.
RESEARCH
During my professional career, physicians have
constantly referred to Virchow’s triad when trying
to explain the basis for the development of DVT. In
its simplest terms, it provides the broad definition of
what is needed for thrombosis to occur.13 The 3
major parts are stasis, intimal injury, and hypercoag-
ulability. These intuitively make a lot of sense, but
when we attempt to define in quantitative terms
each element of the triad, we get into trouble. Let’s
deal with each of these elements and elaborate on
the problems involved.
Stasis. I have never met a physician who did not
appear to have an intuitive understanding of what
stasis means. However, when asked to explain or
quantify what is meant by this word, they get into
trouble. Slowing of blood flow is what stasis means,
but how, when, and where? One needs to look at the
sites where thrombi occur to come to grips with this
concept. From studies with I-125 labeled fibrino-
gen, it is known that the origins of thrombi appear
to be most commonly in the sinuses of the soleus
muscle and the sinuses of the venous valves.14 If one
lies quietly and examines the residence time of con-
trast agents, it appears that the dye does tend to
linger longer here than at other sites. This would
appear to confirm the thesis that stasis must play
some role, and the thesis is further suggested by the
relationship between the development of DVT 
and the “quiet” patient on the operating table or 
the somnolent patient on a long-distance flight.
However, there are still no quantifiable data on how
long this residence time must be for the process to
become initiated in conjunction with activation of
the coagulation cascade.
Intimal injury. Because we know that healthy
endothelium does not support or encourage the
development of thrombi, something must take place
at this level to promote the development of throm-
bosis. Short of direct trauma to the vein wall with
frank intimal disruption, it has been very difficult to
identify problems with the endothelium that help
initiate this process. We don’t have methods avail-
able to study the endothelium directly. In addition,
we don’t have access to the area before or at the time
of the thrombosis to assess what transpired. One
intriguing experimental finding was that of Stewart,
who demonstrated the separation of the intercellular
connections permitting the attraction of leukocytes
to the area and the beginning of thrombosis.15
Interestingly, this would occur in response to injury
at a site remote from where the thrombosis
occurred. Does this answer the second dilemma with
regard to Virchow’s triad?
Hypercoagulability. It is obvious that when
DVT occurs it is rarely a systemic phenomenon, but
is usually confined to a specific venous segment.
However, with the recent emphasis on the role of
genetic factors along with identifiable markers, we
have for the first time culprits to which we can
attribute at least some of the cases that we see clini-
cally. However, this is obviously not a major con-
tributor, as evidenced by the large number of people
with the disorder who never develop DVT and the
much larger number of people who will have only 1
episode in their lifetime associated with the situa-
tions commonly recognized as playing a role. For
example, the recurrence rate for DVT in patients
with established disease is in the range of 10%, and
this is most often associated with a traumatic event
that was often minor.
THE ROLE OF INFLAMMATION
Traditionally, the process associated with DVT
has been referred to as thrombophlebitis. In clinical
practice, this would appear to be a misnomer,
because the only form of venous thrombosis that has
the classical clinical features of inflammation involves
the superficial veins. I don’t believe there is an asso-
ciation or similarity between involvement of the
superficial and deep venous system. In fact, inflam-
mation that produces the classical clinical signs of
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infection is unusual when the deep venous system is
involved. This is why many investigators, including
myself, prefer the term thrombosis without the
attached qualifier.
However, Wakefield and his colleagues have pro-
vided us with some interesting insights and clues as
to the role of an inflammatory response in the
pathogenesis of DVT.16 The views expressed by
these authors can be summarized to some degree by
the stages in this process described by Stewart15 and
can be summarized as follows:
1. Thrombosis that is the major stimulus for inflam-
mation occurs at sites of cellular separation.
2. Continued activation of the platelets and neu-
trophils at the site of the thrombosis will gener-
ate procoagulant and inflammatory mediators
that further amplify the initial process.
3. In the third stage, coagulation proceeds more
rapidly, and the thrombus grows in size.
4. Continued layering of white cells and platelets
occurs as the thrombus enlarges.
In this consideration of events, there are complex
factors at each stage that either promote the process
or halt it in its tracks. As noted by Wakefield, an
inflammatory response might well down-regulate
thrombomodulin and increase C4b binding protein,
decreasing the free protein S availability for protein C
cofactor activity, and thus diminishing its ability to
act as an effective natural anticoagulant.16 Most of us
working in this field have downplayed the role of
inflammation in the development of DVT. However,
based on the work of Wakefield, we may have to
rethink this process, because his early data using MRI
suggests that it may be important at the clinical level
as well. If inflammation with infiltration of the
venous wall does occur, it leads to another critically
important question, which is, what is the relationship
of inflammation to the long-term damage to the wall
and the venous valves? It is well known that there are
2 processes that lead to the long-term sequelae of the
post-thrombotic syndrome, which is chronic venous
obstruction either alone or in combination with loss
of venous valve function.17-19 The 2 competing
processes that are going on simultaneously when
DVT occurs are continued thrombosis and lysis. It
appears that the long-term outcome will depend on
which of these 2 processes is dominant. In addition,
we have shown that inadequate levels of anticoagula-
tion are common both during the acute and chronic
phase of therapy. When this occurs, ongoing throm-
bosis can occur, leading to further venous damage.
These studies further emphasize the need for better
and more controllable levels of anticoagulation.
INTRINSIC THROMBOLYSIS
If the studies done in our laboratory are correct,
the outcome after an episode of DVT can be
explained in large part by the extent to which spon-
taneous thrombolysis occurs and by its relationship
to the preservation of patency and valve func-
tion.18,19 It should have been suspected before the
readily available imaging techniques were developed
that this had to be occurring. In 1981, Browse rec-
ognized that there was very little relationship
between the extent of the thrombosis at the time of
its detection and long-term outcome.20 Our long-
term study published in 1983, which used indirect
testing, showed that up to 40% of patients with an
episode of DVT would never have a complaint in the
long-term.21 This could have only 1 of 2 possible
explanations. The first is that chronic venous
obstruction and the lack of sufficient collaterals
could explain who developed the post-thrombotic
syndrome. Likewise, if a patient was totally symptom-
free, this might be explained by the more efficient
collateral development. Another explanation that
seems more plausible now is that spontaneous
thrombolysis can occur and be most effective in
restoring venous patency and preserving valve func-
tion. This has been suggested by some of our data
taken during long-term follow-up studies.
If thrombolysis is important, can we identify who
will benefit from it and who will not? This problem
is being addressed by Northeast et al22 and others,
and it is, in my view, one of the more exciting areas
for research in the next several years.
THERAPY
It would appear from the programs of this soci-
ety that we are just interested in the wrecks that fol-
low the acute process. This is, in my view, a terrible
mistake, because I believe strongly that we must play
a role in defining the role of therapy during the
acute phase and its effect on long-term venous func-
tion. How then can we contribute? Many members
of this society have been pioneers in the study of
venous function and physiology, defining how and
why patients with DVT get into trouble. How is this
understood by our colleagues interested in throm-
bosis and “thromboembolism”? I think this can be
summarized by the response of Levine to a letter I
submitted to the New England Journal of Medicine
having to do with the use of low-molecular weight
heparin for outpatient therapy for DVT.23 I was con-
cerned that failure to consider suitable candidates for
catheter-directed thrombolysis might prevent some
patients from benefitting from therapy that might
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result in preservation of the lumen and valve func-
tion. Levine’s response to my letter was23,24: “The
most clinically relevant outcome measures—recur-
rent deep-vein thrombosis, pulmonary embolism,
and bleeding—were used in the trial. The extent of
recanalization, the status of the venous valves, or the
extent of residual venous obstruction may be of
physiologic interest, but they are not important clin-
ical outcomes.”
This is, to me, an unbelievable response in 1997.
How could Levine not understand that the changes
that are observed in the deep venous system are crit-
ical to outcome? I believe this is caused by another
problem that those of us who work in this field must
come to recognize. It is very important for us to
publish some of our best work in high quality non-
surgical journals. It is very clear that we read their
literature more often then they do ours. In fact, I
would be surprised if even the best of the surgical
journals are read by our nonsurgical colleagues. I
believe this is a real problem.
TREATMENT ALGORITHMS
Deep vein thrombosis is one entity that is treat-
ed by nearly all specialties in medicine. This is
because, until the present time, the treatment has
appeared to be standard, with very little confusion as
to how it should be done. The protocol was straight-
forward, with the giving of heparin followed by
Coumadin for a period of 6 months. The only sig-
nificant change in this approach was the adoption of
the International Reference Standard (INR) as a
better method of standardizing and controlling the
level of Coumadin therapy.
However, several things have begun to occur
that are changing our approach to the problem. The
first is the recognition that conventional therapy
may be inadequate given the high recurrence rate
and the appearance of low-molecular weight
heparin. These new heparin preparations have the
promise of making the early phase of anticoagulation
more certain and predictable in outcome. In addi-
tion, the promise that therapy can now be done on
an outpatient basis is particularly significant. In addi-
tion, the duration of anticoagulation therapy is open
to question as well.
How can we, as a group, affect therapy both in
the acute and chronic phase? The first and most
obvious way is to promote good educational efforts
for our colleagues, who look to us for direction.
This can be accomplished through workshops and
tutorials, and, most importantly, with the promo-
tion of good clinical trials looking at outcome.
These can be randomized trials or vigorously con-
trolled case-control studies.
We must also be able to promote the study of
newer forms of therapy, whether they are surgical or
nonsurgical. For example, continued work on venous
valve surgery, the perfection of the technique, and
the development of the “perfect” valve must be con-
tinued. Similarly, the resurrection of the perforator
interruption methods must proceed to determine if
this new approach will produce lasting benefit with-
out the high incidence of wound breakdown.
PREVENTION
Although one might think that all the work that
needs to be done is done, this is not the case. We
have new drugs, such as the low-molecular weight
heparins, that are going to play an important role,
and we should participate in their evaluation.25,26
However, unless we undertake an evaluation of their
effects on the deep veins and their valves, it will not
be done. Likewise, the role of compression therapy
by either stockings alone or pneumatic devices con-
tinues to excite a lot of interest from both a clinical
and research standpoint.
LYMPHEDEMA
Perhaps one of the most perplexing and difficult
problems seen is lymphedema, which can occur from
a variety of causes. This entity is frequently confused
with the edema seen in chronic venous insufficiency,
although the distinction is rather simple from a clin-
ical standpoint. The greatest challenge is in its ther-
apy, which most physicians know very little about. It
is not simply a matter of giving a diuretic and pre-
scribing elastic support hose. More hospitals are
developing lymphedema centers that are attracting
large numbers of patients who simply do not have a
home. The management of lymphedema is complex
and life-long, and it is critical if the patients are to
lead a relatively healthy life. We should begin dia-
logue among ourselves about this interesting area of
circulation.
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